東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁 到查詢結果 [ null ]

切換: 標籤 | MARC模式 | ISBD

IRF8-Driven Reprogramming of the Imm...

Montoya, Megan Lilly,

FindBook

Google Book

Amazon

博客來

IRF8-Driven Reprogramming of the Immune Microenvironment Enhances Anti-Tumor Adaptive Immunity and Reduces Immunosuppression in Murine Glioblastoma /

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	IRF8-Driven Reprogramming of the Immune Microenvironment Enhances Anti-Tumor Adaptive Immunity and Reduces Immunosuppression in Murine Glioblastoma // Megan Lilly Montoya.
作者:	Montoya, Megan Lilly,
面頁冊數:	1 electronic resource (117 pages)
附註:	Source: Dissertations Abstracts International, Volume: 86-03, Section: B.
Contained By:	Dissertations Abstracts International86-03B.
標題:	Immunology. -
電子資源:	https://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=31332767
ISBN:	9798384077176

IRF8-Driven Reprogramming of the Immune Microenvironment Enhances Anti-Tumor Adaptive Immunity and Reduces Immunosuppression in Murine Glioblastoma /
Montoya, Megan Lilly,

IRF8-Driven Reprogramming of the Immune Microenvironment Enhances Anti-Tumor Adaptive Immunity and Reduces Immunosuppression in Murine Glioblastoma /Megan Lilly Montoya. - 1 electronic resource (117 pages)

Source: Dissertations Abstracts International, Volume: 86-03, Section: B.

Glioblastoma (GBM) has a highly immunosuppressive tumor immune microenvironment (TIME), largely mediated by myeloid-derived suppressor cells (MDSCs). Here, we utilized a retroviral replicating vector (RRV) to deliver Interferon Regulatory Factor 8 (IRF8), a master regulator of type 1 conventional dendritic cell (cDC1) development, in a syngeneic murine GBM model. We hypothesized that RRV-mediated delivery of IRF8 could "reprogram" intratumoral MDSCs into antigen-presenting cells (APCs) and thereby restore T-cell responses. Effects of RRV-IRF8 on survival and tumor growth kinetics were examined in the SB28 murine GBM model. Immunophenotype was analyzed by flow cytometry and gene expression assays. We assayed functional immunosuppression and antigen presentation by ex vivo T-cell-myeloid co-culture. Mice with RRV-IRF8 intracerebral tumors had significantly longer survival and slower tumor growth compared to controls. RRV-IRF8 treated tumors exhibited significant enrichment of cDC1s and CD8+ T-cells. Additionally, myeloid cells derived from RRV-IRF8 tumors showed decreased expression of the immunosuppressive markers Arg1 and IDO1 and demonstrated reduced suppression of naive T-cell proliferation in ex vivo co-culture, compared to controls. Furthermore, DCs from RRV-IRF8 tumors showed increased antigen presentation compared to those from control tumors. In vivo treatment with azidothymidine (AZT), a viral replication inhibitor, showed that IRF8 transduction in both tumor and non-tumor cells is necessary for survival benefit, associated with a reprogrammed, cDC1- and CD8 T-cell-enriched TIME. Our results indicate that reprogramming of glioma-infiltrating myeloid cells by in vivo expression of IRF8 may reduce immunosuppression and enhance antigen presentation, achieving improved tumor control.

English

ISBN: 9798384077176Subjects--Topical Terms:

611031
Immunology.
Subjects--Index Terms:

Gene therapy

IRF8-Driven Reprogramming of the Immune Microenvironment Enhances Anti-Tumor Adaptive Immunity and Reduces Immunosuppression in Murine Glioblastoma /
LDR:03445nmm a22004573i 4500 001 2436498
005 20251023121228.5
006 m o d
007 cr|nu||||||||
008 261011s2024 miu||||||m |||||||eng d
020 $a 9798384077176
035 $a (MiAaPQD)AAI31332767
035 $a AAI31332767
040 $a MiAaPQD $b eng $c MiAaPQD $e rda
100 1 $a Montoya, Megan Lilly, $e author. $0 (orcid)0000-0002-9465-3146 $3 3827165
245 1 0 $a IRF8-Driven Reprogramming of the Immune Microenvironment Enhances Anti-Tumor Adaptive Immunity and Reduces Immunosuppression in Murine Glioblastoma / $c Megan Lilly Montoya.
264 1 $a Ann Arbor : $b ProQuest Dissertations & Theses, $c 2024
300 $a 1 electronic resource (117 pages)
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
500 $a Source: Dissertations Abstracts International, Volume: 86-03, Section: B.
500 $a Advisors: Barcellos-Hoff, Mary Helen Committee members: Okada, Hideho; Costello, Joseph; Kasahara, Noriyuki.
502 $b Ph.D. $c University of California, San Francisco $d 2024.
520 $a Glioblastoma (GBM) has a highly immunosuppressive tumor immune microenvironment (TIME), largely mediated by myeloid-derived suppressor cells (MDSCs). Here, we utilized a retroviral replicating vector (RRV) to deliver Interferon Regulatory Factor 8 (IRF8), a master regulator of type 1 conventional dendritic cell (cDC1) development, in a syngeneic murine GBM model. We hypothesized that RRV-mediated delivery of IRF8 could "reprogram" intratumoral MDSCs into antigen-presenting cells (APCs) and thereby restore T-cell responses. Effects of RRV-IRF8 on survival and tumor growth kinetics were examined in the SB28 murine GBM model. Immunophenotype was analyzed by flow cytometry and gene expression assays. We assayed functional immunosuppression and antigen presentation by ex vivo T-cell-myeloid co-culture. Mice with RRV-IRF8 intracerebral tumors had significantly longer survival and slower tumor growth compared to controls. RRV-IRF8 treated tumors exhibited significant enrichment of cDC1s and CD8+ T-cells. Additionally, myeloid cells derived from RRV-IRF8 tumors showed decreased expression of the immunosuppressive markers Arg1 and IDO1 and demonstrated reduced suppression of naive T-cell proliferation in ex vivo co-culture, compared to controls. Furthermore, DCs from RRV-IRF8 tumors showed increased antigen presentation compared to those from control tumors. In vivo treatment with azidothymidine (AZT), a viral replication inhibitor, showed that IRF8 transduction in both tumor and non-tumor cells is necessary for survival benefit, associated with a reprogrammed, cDC1- and CD8 T-cell-enriched TIME. Our results indicate that reprogramming of glioma-infiltrating myeloid cells by in vivo expression of IRF8 may reduce immunosuppression and enhance antigen presentation, achieving improved tumor control.
546 $a English
590 $a School code: 0034
650 4 $a Immunology. $3 611031
650 4 $a Biology. $3 522710
650 4 $a Genetics. $3 530508
650 4 $a Cellular biology. $3 3172791
650 4 $a Oncology. $3 751006
653 $a Gene therapy
653 $a Glioblastoma
653 $a Immunosuppression
653 $a Retroviral replicating vector
653 $a Myeloid derived suppressor cells
690 $a 0982
690 $a 0306
690 $a 0369
690 $a 0379
690 $a 0992
710 2 $a University of California, San Francisco. $b Biomedical Sciences. $e degree granting institution. $3 3827166
720 1 $a Barcellos-Hoff, Mary Helen $e degree supervisor.
773 0 $t Dissertations Abstracts International $g 86-03B.
790 $a 0034
791 $a Ph.D.
792 $a 2024
856 4 0 $u https://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=31332767